Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.

Autor: Ball JP; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Springer MJ; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Ni Y; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Finger-Baker I; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Martinez J; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Hahn J; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Suber JF; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., DiMarco AV; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Talton JD; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America., Cobb RR; Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America.

Publikováno v: PloS one [PLoS One] 2017 May 18; Vol. 12 (5), pp. e0177310. Date of Electronic Publication: 2017 May 18 (Print Publication: 2017).